Your browser is no longer supported. Please, upgrade your browser.
Index- P/E- EPS (ttm)-2.86 Insider Own2.94% Shs Outstand43.62M Perf Week-6.81%
Market Cap191.59M Forward P/E- EPS next Y-2.96 Insider Trans0.34% Shs Float42.39M Perf Month-28.60%
Income-119.00M PEG- EPS next Q-0.79 Inst Own86.40% Short Float4.52% Perf Quarter-38.83%
Sales- P/S- EPS this Y-24.30% Inst Trans-1.07% Short Ratio5.60 Perf Half Y-56.52%
Book/sh4.44 P/B0.89 EPS next Y-5.10% ROA-49.00% Target Price22.88 Perf Year-71.70%
Cash/sh4.17 P/C0.95 EPS next 5Y- ROE-52.80% 52W Range4.02 - 20.07 Perf YTD-71.52%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.22% Beta1.33
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin- 52W Low-1.24% ATR0.39
Employees121 Current Ratio9.30 Sales Q/Q- Oper. Margin- RSI (14)26.05 Volatility10.43% 8.06%
OptionableYes Debt/Eq0.00 EPS Q/Q25.90% Profit Margin- Rel Volume1.39 Prev Close4.08
ShortableYes LT Debt/Eq0.00 EarningsNov 04 BMO Payout- Avg Volume342.37K Price3.97
Recom2.00 SMA20-23.92% SMA50-27.92% SMA200-52.60% Volume476,464 Change-2.70%
Nov-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $24 → $7
Jun-15-21Initiated BTIG Research Buy $23
May-27-21Initiated Needham Buy $28
Mar-09-21Initiated Barclays Overweight $23
Mar-02-21Initiated Stifel Hold $14
Nov-11-20Initiated Berenberg Buy
Mar-31-20Downgrade H.C. Wainwright Buy → Neutral $13
Jun-27-19Initiated Mizuho Buy $28
Apr-05-19Initiated Janney Buy
Oct-10-18Initiated Guggenheim Buy
Oct-02-18Reiterated H.C. Wainwright Buy $47 → $40
Sep-17-18Initiated H.C. Wainwright Buy $47
Jul-16-18Initiated Wells Fargo Outperform $40
Jul-16-18Initiated Wedbush Outperform $38
Jul-16-18Initiated Morgan Stanley Overweight $37
Nov-24-21 07:00AM  
Nov-09-21 07:00AM  
Nov-08-21 07:00AM  
Nov-05-21 07:00AM  
Nov-04-21 07:00AM  
Nov-03-21 07:00AM  
Oct-26-21 07:00AM  
Oct-20-21 07:00AM  
Oct-19-21 07:00AM  
Oct-06-21 07:00AM  
Oct-05-21 07:00AM  
Sep-05-21 08:25AM  
Sep-03-21 04:01PM  
Sep-01-21 07:00AM  
Aug-05-21 07:00AM  
Aug-04-21 07:00AM  
Aug-02-21 07:00AM  
Jul-12-21 08:49AM  
Jul-08-21 07:00AM  
Jun-27-21 01:39PM  
Jun-17-21 09:43AM  
Jun-10-21 07:00AM  
Jun-07-21 01:37PM  
Jun-04-21 07:00AM  
May-13-21 07:00AM  
May-12-21 08:32AM  
May-06-21 01:49PM  
May-05-21 10:24AM  
May-04-21 03:40PM  
May-03-21 09:42AM  
Apr-27-21 04:30PM  
Apr-20-21 12:00PM  
Apr-06-21 07:00AM  
Mar-18-21 07:00AM  
Mar-05-21 07:00AM  
Mar-01-21 07:00AM  
Feb-25-21 07:00AM  
Feb-08-21 08:07AM  
Feb-05-21 04:05PM  
Feb-01-21 07:00AM  
Jan-22-21 07:00AM  
Jan-19-21 07:00AM  
Jan-08-21 07:00AM  
Jan-07-21 07:00AM  
Dec-16-20 10:46AM  
Dec-04-20 07:00AM  
Nov-24-20 04:19PM  
Nov-19-20 10:06PM  
Nov-17-20 07:00AM  
Nov-06-20 07:00AM  
Nov-05-20 07:00AM  
Oct-29-20 07:00AM  
Oct-26-20 07:00AM  
Oct-21-20 07:00AM  
Oct-06-20 07:00AM  
Oct-05-20 07:00AM  
Sep-29-20 10:48AM  
Sep-28-20 07:00AM  
Sep-25-20 07:00AM  
Sep-04-20 07:00AM  
Sep-03-20 07:00AM  
Aug-12-20 09:41AM  
Aug-07-20 07:00AM  
Aug-06-20 07:00AM  
Aug-05-20 07:00AM  
Jul-27-20 08:23AM  
Jul-08-20 07:00AM  
Jul-06-20 07:00AM  
Jun-29-20 07:00AM  
Jun-24-20 04:16PM  
May-14-20 07:00AM  
May-13-20 07:00AM  
May-09-20 08:36AM  
May-08-20 08:42AM  
May-07-20 07:00AM  
May-06-20 04:05PM  
May-05-20 07:00AM  
May-04-20 07:00AM  
Apr-14-20 08:58AM  
Apr-12-20 02:26PM  
Apr-03-20 07:00AM  
Mar-30-20 04:30PM  
Mar-26-20 07:00AM  
Mar-25-20 07:47PM  
Mar-19-20 12:00PM  
Mar-17-20 05:58PM  
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vickers Philip J.DirectorJul 07Buy8.354,80040,0804,800Jul 08 04:21 PM
Donenberg Phillip B.DirectorFeb 17Buy11.712,00023,4202,000Feb 18 07:06 PM
MACKAY GEOFFREYPresident & CEODec 24Option Exercise0.41100,00041,320245,123Dec 28 07:46 PM